Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme

Martin K. Hunn, Evelyn Bauer, Catherine E. Wood, Olivier Gasser, Marina Dzhelali, Lindsay R. Ancelet, Brigitta Mester, Katrina J. Sharples, Michael P. Findlay, David A. Hamilton, Ian F. Hermans

Research output: Contribution to journalArticleResearchpeer-review

33 Citations (Scopus)


There is no standard treatment for recurrent glioblastoma multiforme (GBM). Retreatment with temozolomide (TMZ) is one treatment option. We reasoned this could be more effective if combined with a vaccine that preferentially targeted TMZ-resistant cells. To test the feasibility and safety of such an approach, a phase 1 trial was conducted in which patients with GBM tumors relapsing after standard chemoradiotherapy were retreated with TMZ in combination with a vaccine consisting of monocyte-derived dendritic cells (DC) pulsed with autologous tumor cells that had previously been exposed to TMZ in vivo in the course of primary treatment. Of 14 participants, nine patients completed the initial phase of priming vaccinations and two cycles of TMZ, one proved to have radionecrosis, one rapidly progressed, and in three the yield of DC vaccine was insufficient to proceed with treatment. Other than expected toxicities related to TMZ, there were no adverse events attributable to the combined treatment. Two patients had objective radiological responses. Six month progression-free survival was 22 %, similar to retreatment with TMZ alone. Anti-tumor immune responses were assessed in peripheral blood mononuclear cells using interferon-γ ELISpot, with two patients meeting criteria for a vaccine-induced immune response, one of whom remained disease-free for nearly three years. Another patient with an anti-tumor immune response at baseline that was sustained post-vaccination experienced a 12-month period of progression-free survival. In summary, the combined treatment was safe and well-tolerated but feasibility in the recurrent setting was marginal. Evidence of immune responses in a few patients broadly correlated with better clinical outcome.

Original languageEnglish
Pages (from-to)319-329
Number of pages11
JournalJournal of Neuro-Oncology
Issue number2
Publication statusPublished - Jan 2015
Externally publishedYes


  • Chemoresistance
  • Combination therapy
  • Dendritic cell-based vaccination
  • Glioblastoma multiforme
  • T cells
  • Temozolomide

Cite this